Vinorelbine — Drug Intelligence | 34 EU Trials

Filter these 34 trials by condition, phase, country and more.

Open in Search →

34 Registered trials

14 Recruiting

15 Completed trials

25 Sponsors

20 Countries

Phase III

Phase II

Phase I/II

Phase III: 16 Phase II: 10 Phase I/II: 6 Phase IV: 1 Phase I (FiH): 1

Oversight events:

1 serious breach 1 urgent safety measure across 2 trials

View oversight register →

Indications tested

Non-small cell lung cancer 4 Diffuse large B-cell lymphoma 4 Breast cancer 2 Non-small cell lung cancer stage IV 2 Breast cancer metastatic 2 Ewing's sarcoma 2 Mantle cell lymphoma 1 Non-small cell lung cancer stage III 1 Ovarian cancer recurrent 1 Chronic lymphocytic leukaemia 1 Interstitial lung disease 1 Non-small cell lung cancer stage I 1

Sponsors using this IMP

AstraZeneca AB 4 F. Hoffmann-La Roche AG 3 Fondazione Italiana Linfomi Ets 3 Genmab A/S 2 Institut Gustave Roussy 2 Intergroupe Francophone De Cancerologie Thoracique 2 Alx Oncology Inc. 1 Azienda Ospedaliera Universitaria Meyer IRCCS 1 Bristol Myers Squibb International Corporation 1 Champalimaud Clinical Centre 1 Fondazione Santobono Pausilipon Onlus 1 GPOH gGmbH 1

All trials

34 total

A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending

2024-512195-35-00 Phase III 9 countries AstraZeneca AB
Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very Hi… Pending

2024-518912-37-01 Phase II 1 country Fondazione Santobono Pausilipon Onlus
VINORELBINE INHIBITS ONCOGENIC FUNCTIONS OF MKK3: A NEW THERAPEUTIC OPPORTUNITY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER Pending

2024-519459-27-00 Phase II 1 country I.F.O. Istituti Fisioterapici Ospitalieri
Sequential Chemotherapy regimen with vinorelbine and cisplatin plus PET-guided stereotactic ablative radiotherapy (SABR) for castration- and… Pending

2025-521551-23-01 Phase I/II 1 country Tartu University Hospital
Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending

2025-522790-10-00 Phase II 1 country Intergroupe Francophone De Cancerologie Thoracique
A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting

2025-522012-16-00 Phase II 3 countries Alx Oncology Holdings Inc.
A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag… Recruiting

2024-520164-33-00 Phase III 4 countries Maia Biotechnology Inc.
Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting

2024-519971-25-00 Phase III 1 country Intergroupe Francophone De Cancerologie Thoracique
A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best in… Recruiting

2024-517018-14-00 Phase II 1 country Institut Gustave Roussy
INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 Recruiting

2024-511989-36-00 Phase III 5 countries The University Of Birmingham
A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma Recruiting

2024-514635-26-00 Phase III 1 country Medical University Of Gdansk
zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting

2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
Prospective randomized Phase II trial on Induction Immunochemotherapy followed by surgery or definitive chemoradiation and consolidation Dur… Recruiting

2024-516367-80-00 Phase II 1 country Rheinische Friedrich-Wilhelms-Universitaet Bonn
A trial to learn if AZD0486 alone or with other anticancer drugs is safe and works in adults with certain blood cancers Recruiting

2024-515034-33-00 Phase I/II 5 countries AstraZeneca AB
Phase II study to test whether a combination of three drugs—atezolizumab, vinorelbine, and weekly cyclophosphamide—can activate T-cells in p… Recruiting

2024-514031-20-00 Phase II 1 country Istituto Europeo Di Oncologia S.r.l.
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Phase III 8 countries Jazz Pharmaceuticals Ireland Limited
phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate… Recruiting

2024-511631-10-00 Phase I/II 1 country Fondazione Italiana Linfomi Ets
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Phase III 8 countries GPOH gGmbH
AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting

2024-514791-40-00 Phase I/II 5 countries Institut Gustave Roussy
An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with cranio… Ended

2024-518964-11-01 Phase II 1 country Azienda Ospedaliera Universitaria Meyer IRCCS
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Phase II 9 countries AstraZeneca AB
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 Phase III 7 countries AstraZeneca AB
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended

2024-511636-27-00 Phase III 1 country Fondazione Italiana Linfomi Ets
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Phase III 11 countries Incyte Corp.

Showing 1–24 of 34 trials

← All drugs A–Z